SCHEMBL7941383

SCHEMBL7941383

COc1ccc(C(=O)Nc2ccnc(CNc3cccnc3N)c2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 0.53
NPC1 O15118 4/20 0.53
BACE1 P56817 2/20 0.52
PPARG P37231 1/20 0.51
RXFP1 Q9HBX9 1/20 0.51
NCOR2 Q9Y618 1/20 0.51
HDAC1 Q13547 5/20 0.50
KMT2A Q03164 4/20 0.50
MEN1 O00255 2/20 0.50
POLB P06746 1/20 0.50
HDAC3 O15379 2/20 0.49
HDAC4 P56524 2/20 0.49
HDAC7 Q8WUI4 2/20 0.49
HDAC2 Q92769 2/20 0.49
HDAC10 Q969S8 2/20 0.49
HDAC11 Q96DB2 2/20 0.49
HDAC8 Q9BY41 2/20 0.49
HDAC6 Q9UBN7 2/20 0.49
HDAC9 Q9UKV0 2/20 0.49
HDAC5 Q9UQL6 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7941890 0.88 BACE1 (0.59) RAB9ANPC1BACE1PKMSMN1; SMN2
SCHEMBL7940998 0.87 GAA (0.50) RAB9ANPC1BACE1HDAC1KMT2A
SCHEMBL7940344 0.86 BACE1 (0.69) RAB9ANPC1BACE1HDAC1KMT2A
SCHEMBL7942900 0.85 PTGS1 (0.49) RAB9ANPC1RXFP1KMT2AMEN1
SCHEMBL7943413 0.84 BACE1 (0.50) BACE1KMT2AALDH1A1
SCHEMBL7935760 0.84 BACE1 (0.50) BACE1
SCHEMBL7944993 0.84 HPGD (0.49) RAB9ANPC1BACE1RXFP1KMT2A
SCHEMBL7945674 0.83 AURKA (0.61) RAB9ANPC1BACE1PPARGRXFP1
SCHEMBL7941938 0.83 BACE1 (0.49) BACE1HDAC1AURKARPS6KB1AURKB
SCHEMBL7943411 0.82 NPC1 (0.57) RAB9ANPC1RXFP1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110237576-A1 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY SHIONOGI & CO., LTD. (JP) 2011-09-29 US disclosed
EP-2360155-A1 2-AMINOPYRIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVE BOTH HAVING BACE1-INHIBITING ACTIVITY Shionogi & Co., Ltd. (JP) 2011-08-24 EP disclosed
WO-2010047372-A1 2-AMINOPYRIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVE BOTH HAVING BACE1-INHIBITING ACTIVITY 塩野義製薬株式会社 (JP) 2010-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237576-A1 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY BACE1, APP, BACE2 RAB9A 1287/4885NPC1 431/4885BACE1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.